Human Germline Heterozygous Gain-of-Function STAT6 Variants Cause Severe Allergic Disease

- Mehul Sharma^{1,2}, Henry Y. Lu^{1,2}, Maryam Vaseghi-Shanjani^{1,2}, Kate L. Del Bel¹, Oriol 3 Fornes^{3,4}, Robin van der Lee^{3,4}, Phillip A. Richmond^{1,3}, Susan Lin¹, Joshua Dalmann¹, 4 Jessica J. Lee^{3,5}, Allison Matthews³, Géraldine Blanchard-Rohner^{1,6}, Clara D M van 5 Karnebeek^{3,7}, H. Melanie Bedford^{8,9}, Wyeth W. Wasserman³, Michael Seear¹, Margaret 6 L. McKinnon⁴, Hanan Ahmed¹⁰, Stuart E. Turvey^{1,2} 7 ¹Department of Pediatrics, BC Children's Hospital, The University of British Columbia, 8 Vancouver, British Columbia, Canada 9 ²Experimental Medicine Program, Faculty of Medicine, The University of British 10 Columbia, British Columbia, Canada 11 ³Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research 12 Institute, Vancouver, BC, Canada 13 ⁴Department of Medical Genetics, University of British Columbia, Vancouver, BC, 14 Canada 15 ⁵Genome Science and Technology Graduate Program, University of British Columbia, 16 17 Vancouver, BC, Canada. ⁶Unit of Immunology and Vaccinology, Division of General Pediatrics, Department of 18 19 Woman, Child, and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland. 20 ⁷Departments of Pediatrics and Clinical Genetics, Amsterdam University Medical 21 22 Centers, Amsterdam, The Netherlands 23 ⁸Genetics Program, North York General Hospital, 4001 Leslie Street, Toronto, Ontario, Canada. 24 ⁹Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. 25 26 ¹⁰Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada 27 **Correspondence to:** Stuart E. Turvey, MBBS, DPhil, FRCPC 28 BC Children's Hospital 29 950 West 28th Avenue 30 Vancouver, BC, V5Z 4H4, Canada 31 Phone: 604 875 2345 ext. 5094 32 33 Email: sturvey@cw.bc.ca
- 34 **Running Title:** Human germline STAT6 gain-of-function variants
- 35 Word Count: 4439
- 36 Abstract Word Count: 209
- 37 **Figure Count:** 4
- 38 **Reference Count:** 98
- 39

Human germline STAT6 gain-of-function variants

Sharma *et al.*

40 ABSTRACT

STAT6 (Signal transducer and activator of transcription 6) is a transcription factor that 41 plays a central role in the pathophysiology of allergic inflammation. STAT6 mediates the 42 biological effects of IL-4, a cytokine necessary for type 2 differentiation of T cells and B 43 cell survival, proliferation and class switching to IgE. We have identificated two 44 unrelated patients with a phenotype notable for their early-life onset of profound allergic 45 immune dysregulation, widespread treatment-resistant atopic dermatitis, 46 hypereosinophilia with esosinophilic esophagitis, elevated serum IgE, IgE-mediated 47 food allergies, and vascular anomalies of the brain. Both patients harbored 48 heterozygous de novo missense variants in the DNA binding domain of STAT6 49 (c.1144G>C, p.E382Q; and c.1256A>G, p.D419G). Functional studies established that 50 both variants caused a gain-of-function (GOF) phenotype associated with enhanced 51 phosphorylation and transcriptional activity of STAT6, in addition to increased transcript 52 abundance of known STAT6 target genes and other genes implicated in allergic 53 disease. JAK inhibitors decreased the enhanced STAT6 responses associated with 54 both these STAT6 GOF variants. This study identifies heterozygous GOF variants in 55 STAT6 as a novel autosomal dominant allergic disorder. We anticipate that our 56 57 discovery of the first humans with germline STAT6 GOF variants will facilitate the recognition of more affected individuals and the full definition of this new primary atopic 58

60

59

disorder.

Human germline STAT6 gain-of-function variants

Sharma et al.

61 **INTRODUCTION**

Signal transducer and activator of transcription (STAT) proteins are a family of seven 62 mammalian transcription factors (STAT1, STAT2, STAT3, STAT4, STAT5A/B, and 63 64 STAT6) responsible for regulating the expression of genes involved in cellular immunity, survival, proliferation, and differentiation^{1,2}. Although they each have unique functions, 65 they share sequence homology and possess similar activation mechanisms³. In 66 general, upon extracellular cytokine/growth factor-receptor engagement, intracellular 67 68 membrane receptor-associated Janus kinases (JAK) undergo transphosphorylation and activation, leading to receptor tyrosine phosphorylation⁴. Phosphorylated tyrosine 69 70 residues on the receptor then create binding sites for the normally cytosolic-located Src 71 homology 2 (SH2) domain-containing STATs to bind and become phosphorylated and 72 activated. Phosphorylated STATs, dimerize and translocate into the nucleus, where they bind to specific DNA sequences and regulate transcription⁴⁻⁷. As such, STATs are 73 critical for transducing extracellular cytokine-induced responses to transcriptional 74

changes in the nucleus.

Signal transducer and activator of transcription 6 (STAT6) is the main transcription 76 factor that mediates the biological effects of IL-4, a cytokine necessary for type 2 77 differentiation of T cells, as well as B cell survival, proliferation and class switching to 78 IgE⁸⁻¹¹. IL-4 is predominantly secreted by T cells, mast cells, basophils, and type 2 79 innate lymphoid cells¹². To mediate its effects, IL-4 binds the widely expressed IL-4Ra 80 and this complex then binds secondary receptors chains¹³. In hematopoietic cells, the 81 secondary receptor chain is the common yc chain also used by IL-2, IL-7, IL-9 and IL-15 82 and this forms the type 1 IL-4R system¹⁴. In non-hematopoietic cells such as epithelial 83 cells, the secondary receptor chain is IL-13R α , which forms the type 2 IL-4R system¹³. 84 85 Activation of these two receptor systems lead to diverse functions. In B cells, IL-4-STAT6 signalling supports the growth and differentiation of B cells as well as secretion 86 of pro-allergic immunoglobulin E (IgE)⁹. In T cells, the IL-4-STAT6 axis is critical for the 87 differentiation of T helper 2 (T_H2) cells¹⁵, a subset of CD4⁺ helper T cells that is a major 88 contributor to the pathogenesis of allergic disease. In epithelial cells, the IL-4/IL-13-89 STAT6 pathway has been implicated in barrier dysfunction^{16,17} and chronic pruritus¹⁸. 90

Human germline STAT6 gain-of-function variants

Sharma et al.

91	Collectively, the IL-4-STAT6 axis drives the development and progression of allergic
92	disease and asthma. Indeed, a monoclonal antibody directed against IL-4R α
93	(dupilumab) is clinically approved for treating allergic inflammation ^{19,20} . Mouse studies
94	further emphasize the central role that STAT6 plays in the allergic diathesis. Mice
95	lacking STAT6 fail to develop many of the features of allergic inflammation ²¹⁻²³ .
96	In 2018, the term primary atopic disorders (PADs) was coined to describe heritable
97	genetic disorders presenting with dysregulated pathogenic allergic effector responses ²⁴⁻
98	²⁶ . PADs are a subgroup of inborn errors of immunity (IEIs) that manifest with prominent
99	allergic inflammation, in the presence or absence of other clinical features associated
100	with IEIs, such as enhanced susceptibility to infections, autoimmunity, and malignancy.
101	Of the ~40 monogenic causes of PADs described to date, 12 impact the JAK-STAT
102	signaling cascade that is critical for cytokine responsiveness. For example, both loss-of-
103	function (LOF) and gain-of-function (GOF) variants in STAT3 ^{27,28} and STAT5B ^{29,30} , and
104	GOF variants in JAK1 ^{31,32} and STAT1 ³³ cause PADs. Furthermore, defects in the genes
105	encoding upstream and downstream proteins in the STAT pathway (e.g. ZNF341,
106	DOCK8, IL6ST, IL6R, and ERBIN) also result in severe allergic diseases ²⁶ . The recent
107	increased recognition of PADs is valuable because: (i) the identification of affected
108	pathways provide important insights into the pathogenesis of allergic inflammation and
109	may uncover new treatment targets; (ii) these conditions are likely under-diagnosed
110	since allergies are traditionally believed to be complex polygenic disorders; and (iii)
111	diagnosis of PADs can be transformative for affected individuals and their families by
112	guiding treatment options, and informing relevant considerations tied to genetic
113	counselling including family planning, long term prognosis, and connection to other
114	families with the same genetic disease.

In this study, we describe a novel human PAD caused by germline heterozygous GOF
variants in the DNA binding domain of *STAT6* found in two unrelated individuals with
severe allergic disease and vascular anomalies of the brain.

118

Human germline STAT6 gain-of-function variants

Sharma et al.

120 METHODS

- 121 Ethical Considerations: All study participants provided written informed consent.
- 122 Research study protocols were approved by The University of British Columbia Clinical
- 123 Research Ethics Board.

124 Identification of STAT6 variant via whole exome sequencing: Trio whole exome

- sequencing (WES) was performed as previously described³⁴. Briefly, WES was
- performed on genomic DNA extracted from the first patient (P1) and both his parents
- and a novel *de novo* predicted damaging *STAT6* variant (c.1144G>C p.E382Q) was
- selected for further analysis. WES was also performed on genomic DNA extracted from
- the second patient (P2), her mother, and one of her brothers. A novel *de novo* predicted
- damaging variant for STAT6 (c.1256A>G, p.D419G) was identified. Sanger sequencing
- on saliva samples collected from the remaining family members of P2 revealed that no
- 132 other individuals carried the variant and that it segregates with disease.

133 Generation of STAT6 variant plasmids: Plasmids used for transfection studies

134 contained full-length STAT6 in a pCMV6 entry vector with a C-terminal GFP tag (Cat#:

- 135 RG210065, OriGene Technologies; Rockville, Maryland, USA). To generate p.E382Q
- and p.D419G STAT6, a Q5 site-directed mutagenesis kit (Cat# E0554S, New England
- 137 Biolabs, Ipswich, MA, USA) was used according to manufacturer's recommendations
- along with the following primer pairs: 5'-TGTCACAGAGCAGAGTGCGC-3', 5'-
- 139 GACTCAGTGCCCTTCCGC-3', and 5'-GGCAACCAAGGCAACAATGCC-3', 5'-
- 140 ATGGACGATGACCACCAG-3', respectively.

To generate lentivirus vectors, wild type (WT), p.E382Q, and p.D419G STAT6 from the
above plasmids were cloned into a GFP-tagged Lenti vector (Cat#: PS100071, OriGene
Technologies, Rockville, MD, United States) using EcoRI-HF (Cat#: R3101) and NotIHF (Cat#: R3189) both from New England BioLabs. The three STAT6 plasmids were
packaged using 3rd generation packaging plasmids and transfected into HEK293T
cells. Culture media was collected, centrifuged, filtered, concentrated, and stored at -

147 80°C before use.

Human germline STAT6 gain-of-function variants

Sharma et al.

- All new variant plasmids were confirmed by Sanger sequencing and purified from 10-
- 149 beta competent *E. coli* using a QIAprep Spin Miniprep Kit (Qiagen, ON, Canada).

Transient and stable expression of STAT6 variants: Transient expression of STAT6
variants in HEK293 cells were accomplished using a Lipofectamine 3000 kit (Thermo
Fisher Scientific, Waltham, MA, USA) according to manufacturer's recommendations.
Briefly, HEK293 cells were seeded at 8.0 × 10⁵ cells/well in a 6-well plate in 1.5 mL of
Dulbecco modified Eagle medium (DMEM) with 10% FBS (Gibco, Life Technologies;
Rockville, MD, USA) and incubated for 24 hours at 37°C. Cells were transfected with
2.5µg of plasmid DNA using the P3000 and Lipofectamine 3000 reagents and harvested

157 after 24h.

158 Stable expression of STAT6 in Jurkat T cells was accomplished using the Lentivirus

- approach as previously described^{35,36}. Briefly, Jurkat T cells were infected with lentiviral
- particles in the presence of 5µg/ml polybrene (Sigma-Aldrich, St Louis, MO, USA) and
- spinoculated at 800 x g for 30mins at 32°C, cultured, and expanded in complete RPMI-
- 162 1640 (GE Healthcare, Chicago, IL, United States) supplemented with 10% FBS.
- 163 Expanded cells were sorted on GFP expression using a BD FACS Aria (BD

164 Biosciences) cell sorter.

Determining STAT6 variant activity by phospho-flow cytometry: Phospho-STAT6 165 activity was quantified by flow cytometry in transfected cells stimulated with 100ng/mL 166 of IL-4 (Cat# 204-IL-020, R & D Systems, Minneapolis, MN, USA) for 1h or transfected 167 cells pre-treated with either 10µM ruxolitinib (Cat code: tlrl-rux, Invivogen, San Diego, 168 CA, USA) or 4µM tofacitinib (Cat# S50001, Selleckchem, Houston, TX, USA) for 2h 169 before stimulation as previously described³⁷. Briefly, transfected and stimulated cells 170 were fixed using BD Cytofix (Cat# 554655, BD Biosciences, Ontario, Canada) for 20 171 min at 4°C and permeabilized using Perm III for 30 min on ice (Cat# 558050 BD 172 Biosciences). The cells were then stained with STAT6 PE-CF594 (Cat# 564148, BD 173 Biosciences) and p-STAT6 AF647 (Cat# 612601, BD Biosciences). pSTAT6 expression 174 was measured in GFP⁺STAT6⁺ cells from WT and STAT6 variants samples on an LSRII 175

Human germline STAT6 gain-of-function variants

Sharma et al.

176 flow cytometer (BD Biosciences) and analyzed using FlowJo software (BD

177 Biosciences).

Luciferase reporter assays: A luciferase reporter plasmid encoding a 4x STAT6 178 179 binding site [TTCCCAAGAA] was used to assess WT and variant STAT6 promoter activity³⁸. The p4xSTAT6-Luc2P plasmid was a gift from Axel Nohturfft (Addgene 180 plasmid #35554; http://n2t.net/addgene:35554; RRID:Addgene 35554). Briefly, HEK293 181 cells were seeded in 24-well plates overnight at a density of 150k cells and transfected 182 with 250ng of p4xSTAT6-Luc2P, 250ng of a plasmid encoding GFP-tagged WT, 183 p.E382Q, or p.D419G STAT6, and 10ng Renilla luciferase (R-Luc) using lipofectamine 184 185 3000 as described above. Transfected cells were subsequently stimulated with 100ng/mL of IL-4 (Cat# 6507-IL-010, R&D Systems, Minneapolis, MN, USA) or left 186 187 untreated. Cell lysates were prepared and processed using a Dual-Glo Luciferase Assay Kit (Cat#: E2920, Promega, Madison, WI, USA) according to manufacturer's 188 recommendations. Luciferase activity was measured on the Infinite M200 plate reader 189 (Tecan; Männedorf, Switzerland). 190

RNA sequencing: To investigate the global transcriptome, STAT6 variant-transduced 191 Jurkat T cells were left unstimulated, or stimulated with 100ng/mL IL-4 for 4h. RNA was 192 extracted in triplicate as previously described³⁷ using a RNeasy Mini Plus Kit (Qiagen) 193 according to manufacturer's recommendations. RNA was prepared following the 194 standard protocol for the NEBNext Ultra II Stranded mRNA (New England Biolabs) and 195 sequenced on the Illumina NextSeq 500 with Paired End 42 bp x 42 bp reads. De-196 multiplexed read sequences were aligned to a reference sequence using RNA-Seq 197 Alignment app (v1.1.1) on Illumina Basespace, using Spliced Transcripts Alignment to a 198 Reference (STAR) aligner and Cufflinks 2 for assembly and estimation of gene 199 200 expression.

Expression data were normalized to reads between samples using the edgeR package in R (R Foundation, Vienna, Austria). Normalized counts were filtered to remove low counts using the filterByExpr function in edgeR³⁹. Principal component analysis (PCA) was done on log₂(normalized counts+0.25) in R using the PCA function. Differential

Human germline STAT6 gain-of-function variants

Sharma et al.

expression between unstimulated and stimulated samples for all three *STAT6*transduced Jurkat T cells was accomplished using Limma⁴⁰. Differentially expressed
genes were defined as those with fold change (FC) greater than 1.25 and adjusted pvalue less than 0.05.

209 Pathway analysis was done by first performing Gene Set Enrichment Analysis (GSEA)

with 1000 permutations using the Molecular Signatures Database Hallmark module.

Signal-to-noise ratio was used for gene ranking and the obtained NESs and P-values

were further adjusted using the Benjamini-Hochberg method. Pathways with an

adjusted P-value < 0.05 were considered significant. Leading edge genes from

significant pathways between STAT6 WT and STAT6 c.1256A>G Jurkat were identified

215 (no significantly upregulated pathways were identified between *STAT6* Wild Type and

216 STAT6 c.1144G>C). Expression levels of these genes were then determined in each of

the three groups (Wild Type, c.1144G>C, c.1256A>G) under both stimulated and

218 unstimulated conditions. Sample level enrichment analyses (SLEA) scores were

computed as previously described⁴¹. Briefly, z-scores were computed for gene sets of

interest for each sample. The mean expression levels of significant genes were

compared to the expression of 1000 random gene sets of the same size. The difference

between observed and expected mean expression was then calculated and represented

on heatmaps.

Gene set enrichment analysis was also done on two other gene sets: i) STAT6 targets;

and ii) IL-4 T_H2 targets. STAT6 targets were defined as the set of genes that were

significantly upregulated upon IL-4 stimulation in WT-STAT6 transduced Jurkat T cells.

227 Enrichment of this gene set was determined at both baseline and after IL-4 stimulation

between WT and p.E382Q STAT6, and WT and p.D419G STAT6 Jurkat T cells. IL-4-

229 STAT6 T_H2 skewing targets were previously reported⁴² STAT6 target genes that are

significantly upregulated in response to IL-4 treatment and that lead to T_{H2} skewing.

Raw data will be deposited on Gene Expression Omnibus.

Structural modeling: The effects of the STAT6 variants on the protein function and
 structure were analyzed using three-dimensional models. We used SWISS-MODEL⁴³ to

Human germline STAT6 gain-of-function variants

Sharma et al.

- model the variants based on a template structure of the human STAT6 transcription
- factor solved as a homodimer and in complex with DNA (PDB: 4Y5W, resolution: 3.1 Å,
- chains A, C, M and N)³⁸. Structures were visualized with UCSF Chimera⁴⁴.

237

Human germline STAT6 gain-of-function variants

Sharma et al.

239 **RESULTS**

240 Clinical features of two patients with severe atopic disease

Patient A-II-1 (P1) was a male patient who had life-long severe allergic disease. The 241 patient was not dysmorphic and was born to unrelated parents. Soon after birth, P1 242 243 developed widespread, treatment-resistant atopic dermatitis (eczema), gastroesophageal reflux with episodes of aspiration pneumonia, as well as chronic 244 diarrhea. He underwent Nissen fundoplication a few months later (with a surgical 245 revision in early childhood, age 6-10 years), following which gastrostomy feeding was 246 247 commenced. Over time, he was also diagnosed with multiple food and drug allergies with anaphylactic reactions (combined with positive skin prick testing or RAST testing) 248 documented in response to peanuts, cows milk protein, bananas, sesame seeds, fish, 249 and eggs. He was fed with extensively hydrolyzed and elemental formulas via 250 gastrostomy with very limited oral feeding for much of his life. He was also diagnosed 251 with asthma. He experienced episodes of secondary bacterial skin infections from which 252 Staphylococcus aureus, group A streptococci and Candida spp. were isolated. 253 Widespread molluscum contagiosum was another notable skin finding. In his second 254 and third decade of life, he had persisting eczema, asthma, and perennial rhinitis which 255 worsened during pollen seasons. Repeated upper GI endoscopies confirmed the 256 257 diagnosis of eosinophilic esophagitis. During this time, most of his feeding consisted of elemental formula via gastrostomy supplemented with limited oral intake (mainly rice, 258 259 potatoes, and chicken). He was treated with oral steroids for many years and 260 experienced symptom flares whenever the dose of prednisone was dropped below 10mg/day. He developed side-effects related to corticosteroids including cataracts. 261 osteoporosis, and pathogenic fractures. He had an episode of thromboembolic ischemia 262 263 of the right first and third toes with pain and cyanosis, ultimately requiring a lumbar sympathectomy to relieve the pain. In his mid-30s (age 30-35 years), he was 264 hospitalized for non-bloody diarrhea, profound weight loss, malnutrition, weakness, and 265 vertigo. He was treated with high dose of prednisone, antibiotics, and elemental feeding. 266 267 During the hospitalization, he died after developing a spontaneous subarachnoid hemorrhage with obstructive hydrocephalus, presumed secondary to an aneurysm 268

Human germline STAT6 gain-of-function variants

Sharma et al.

(**Table 1**). Blood testing over the years confirmed eosinophilia and high serum IgE

levels (**Fig 1**). Lymphocyte phenotyping and proliferation to a panel of mitogens were

found to be unremarkable when measured in early adulthood (ages 20-25 years). An

initial genetic assessment revealed normal sequences for STAT3 and DOCK8,

273 prompting a more extensive genetic evaluation by WES.

Patient B-II-1 (P2) is a female who had similar life-long struggles with severe allergic
disease. She presented with severe chronic, treatment-resistant atopic dermatitis since

birth. She was diagnosed with IgE-mediated food allergy to egg, milk, peanut and tree

nuts early in life (age 0-5 years). She was diagnosed with asthma as an infant. In her

early life (age 0-5 years) she also had a pneumothorax requiring chest tube insertion,

required intubation for an asthma exacerbation, and was diagnosed with giant papillary

conjunctivitis which has remained an ongoing challenge. Other eye manifestations

included unilateral retinal detachment in her adolescence (age 15-20 years) and the

development of cataracts requiring surgery in early adulthood (age 20-25 years).

283 Through her second and third decades of life she continued to suffer from eczema,

asthma, recurrent bronchitis, rhinoconjunctivitis, and secondary staphylococcal and

285 candida skin infections. She had multiple dental abscess in the second and third

decades of her life. In her 20s she began experiencing gastrointestinal symptoms

culminating in biopsy diagnosed eosinophilic esophagitis and eosinophilic

gastroenteritis. Joint examination confirmed the presence of hypermobility. Serial blood

testing over the years confirmed eosinophilia and high serum IgE levels (**Fig 1**). Brain

290 MRI in her mid-30s (ages 30-35 years) revealed multiple anatomical variants including

anomalous vasculature in the circle of Willis with hypoplastic vertebrobasilar arteries, a

292 persistent left-sided congenital trigeminal artery with tortuosity, and a hypoplastic A1

segment of the right anterior carotid artery (**Table 1**). Multiple therapies were trialed

over the years with corticosteroids offering the most obvious benefits. To seek a
diagnosis for this spectrum of severe allergic manifestations, WES was performed on

the patient, her mother and one of her brothers.

Human germline STAT6 gain-of-function variants

Sharma et al.

298 Whole-exome sequencing reveals novel *de novo* heterozygous variants in the 299 DNA binding domain of *STAT6*

The patients were found to carry heterozygous variants in the gene STAT6 300 301 (NM_001178079.2): c.1144G>C, p.E382Q for P1 and c.1256A>G, p.D419G for P2. The variants were *de novo* as they were not found in any other family members (**Fig 1A**). 302 Both variants have not been reported in population databases (i.e. gnomAD), but 303 p.D419G can be found in the Catalogue of Somatic Mutations in Cancer (COSMIC) 304 305 database as a recurrent somatic variant in lymphoma with experimental evidence of a GOF phenotype for this variant^{45,46}. Pathogenicity prediction models predict both 306 variants to be pathogenic, including CADD (Version 1.6, p.D419G: 29.3, p.E382Q: 307 27.7)⁴⁷, SIFT (p.D419G: 0.001, p.E382Q: 0.026)⁴⁸, and Polyphen-2 (p.D419G: 1.0, 308 309 p.E382Q: 1.0)⁴⁹ (**Supp Table 1**). Clinical laboratory tests showed that both patients had eosinophilia and markedly elevated IgE (Fig 1B-C). Both variants localized to the highly 310 conserved DNA binding domain of STAT6 (Fig 1D). Glu382 and Asp419 lie close to the 311 regions responsible for protein-DNA interaction³⁸. Both of these variants decrease the 312 electro-negativity of the protein near the DNA-binding interface (due to loss of glutamic 313 acid (E) and aspartic acid (D)), and are predicted to enhance STAT6 binding to DNA 314 (Fig 1E). These variants did not affect STAT6 protein expression as measured by flow 315 cytometry in transfected HEK293 cells (Fig 1F-G). 316

317

p.E382Q and p.D419G STAT6 variants lead to increased phosphorylation and transcription activity of STAT6 in HEK293 cells

To assess the functional impact of the p.E382Q and p.D419G STAT6 variants, we selected HEK293 cells as our system, as these cells lack endogenous STAT6 but express other components of the IL-4R pathway (**Fig 2A**)⁵⁰. HEK293 cells were transfected with wild-type (WT), p.E382Q, or p.D419G STAT6 and the phosphorylation status of STAT6 was quantified by flow cytometry after 24h (**Fig 2B**). At baseline, we observed significantly increased phosphorylated STAT6 in cells expressing the p.E382Q and p.D419G variants when compared to WT. IL-4 stimulation led to increased

Human germline STAT6 gain-of-function variants

Sharma et al.

phospho-STAT6 in all conditions, with the variant expressing cells maintaining 327 significantly higher phospho-STAT6 than WT (Fig 2C). To investigate whether 328 increased phosphorylation of STAT6 in both variants lead to increased STAT6 329 transcription factor activity, we conducted luciferase assays with a reporter plasmid 330 containing a canonical 4x STAT6 binding site, TTCCCAAGAA in HEK293 cells³⁸. Both 331 p.E382Q and p.D419G STAT6 variants resulted in significantly higher promoter activity 332 at baseline (Fig 2D). However, there was no significant difference in promoter activity 333 after 4h IL-4 stimulation (Fig 2D). Together these data confirm a GOF phenotype 334 caused by both p.E382Q and p.D419G STAT6 variants. 335

336

p.E382Q and p.D419G STAT6 variants exert a gain-of-function phenotype in Jurkat T cells

Given the increased promoter activity of the p.E382Q and p.D419G STAT6 variants, we

were interested in evaluating how this may impact the global transcriptome. As

341 transcriptomic studies on HEK293 cells after IL-4 stimulation have been challenging to

interpret⁴⁵, we stably expressed p.E382Q and p.D419G STAT6 by lentivirus

transduction in Jurkat T leukemia cells, which express endogenous STAT6 and serve

as a model of heterozygosity⁵¹. Here, we observed significantly higher phospho-STAT6-

positivity at baseline for the p.E382Q- cells but not p.D419G- cells, when compared to

WT (**Fig 3A**). However, there was no significant difference in phospho-STAT6 positivity after IL-4 stimulation (**Fig 3A**).

Transcriptomically, WT-, p.E382Q-, and p.D419G-transduced cells clustered separately 348 from each other both at baseline and after stimulation with IL-4 (Fig 3B). This confirmed 349 that all variant cells were responsive to IL-4, and identified a unique transcriptomic 350 signature for each. Differential gene expression analysis revealed significantly 351 increased transcript abundance of known STAT6 target genes, including IL4R⁵², CISH⁴⁵ 352 and EPAS⁴², and genes that have been implicated in atopic disease, including XBP1⁵³ 353 and TGFBR254 in p.E382Q and p.D419G transduced cells when compared to WT 354 transduced controls (Fig 3C-H). 355

Human germline STAT6 gain-of-function variants

Sharma et al.

In response to IL-4 stimulation, we observed 54, 145, and 159 significantly upregulated
genes in WT-, p.E382Q-, and p.D419G-transduced Jurkat T cells, respectively (Fig 3I,
Supp Fig 2A). Interestingly, p.E382Q and p.D419G had 67 and 80 uniquely increased
hits, which did not overlap with WT, nor with each other. On the other hand, p.E382Q
and p.D419G had 108 and 54 uniquely downregulated genes (Fig 3I, Supp Fig 2A).
This suggests that the altered activity of both p.E382Q and p.D419G is not restricted to
enhanced activity on known STAT6 targets alone.

363 To further investigate the differential gene expression patterns, we performed gene set enrichment analyses (GSEA). We first defined IL-4-STAT6 targets as genes that were 364 365 significantly upregulated in stimulated WT STAT6-transduced Jurkat T cells (Supp Table 2). We found enrichment of these targets in both p.E382Q and p.D419G Jurkats 366 367 only at baseline (p.E382Q NES 1.34, adj-pvalue 0.084; p.D419G NES 1.83, adj-pvalue <0.001), but not after IL-4 stimulation. Notably, after IL-4 stimulation both p.E382Q and 368 p.D419G STAT6 Jurkats showed significantly increased enrichment of IL-4 responsive 369 TH2 skewing targets⁴² (p.E382Q NES 1.56, adj-pvalue <0.001; p.D419G NES 1.52, adj-370 pvalue 0.007)(Fig 3J). 371

GSEA using the MSigDB Hallmark gene sets showed no significant difference in
enrichment in immunological pathways between WT and p.E382Q STAT6 both at
baseline and in response to stimulation (Fig 3K, Supp Table 3). However, p.D419G
STAT6 exhibited significantly increased enrichment in proliferation (Myc, G2M, DNA
repair, E2F) pathways, consistent with the fact that p.D419G (but not p.E382Q) is
reported as a recurrent somatic mutation in lymphoma^{45,55,56}, establishing this variant as
oncogenic.

379

JAK inhibitors reduce enhanced STAT6 phosphorylation induced by p.E382Q and p.D419G STAT6 in HEK293 cells

- Having demonstrated that both p.E382Q and p.D419G STAT6 are GOF variants, we
- tested whether small molecule inhibitors that target the STAT6 pathway could

Human germline STAT6 gain-of-function variants

Sharma et al.

- potentially be clinically beneficial. We selected JAK inhibitors, ruxolitinib and tofacitinib,
- as both of these drugs are already used clinically for treating atopic disease^{57,58}. Both
- inhibitors effectively decreased the enhanced STAT6 phosphorylation observed at
- baseline and after IL-4 stimulation in cells expressing the p.E382Q or p.D419G STAT6
- variants (**Fig 4A-B**). This suggests that JAK inhibitors may be promising treatment
- options for patients with GOF *STAT6* variants.

390

Human germline STAT6 gain-of-function variants

Sharma et al.

392 DISCUSSION

In this study, we present a combination of clinical, molecular, and transcriptional 393 evidence of a new human disorder caused by germline autosomal dominant GOF 394 395 STAT6 variants in two patients with life-long severe allergic disease. These variants led to increased STAT6 phosphorylation, increased STAT6 target gene expression, and 396 T_H2 skewed transcriptional profile. Although the full phenotype of GOF STAT6 variants 397 will only be uncovered through the identification of additional affected individuals, we 398 propose to classify human germline autosomal dominant GOF STAT6 syndrome as a 399 novel primary atopic disorder²⁴⁻²⁶. Based on our study, possible clinical 'red flags' for 400 this new disorder include: (i) early life onset; (ii) peripheral blood eosinophilia, (iii) 401 elevated serum IgE, (iii) widespread, treatment-resistant atopic dermatitis, (iv) multiple 402 403 food and drug allergies; (v) recurrent skin and respiratory infections; (vi) eosinophilic gastrointestinal disorder, including eosinophilic esophagitis; (vii) allergic 404

rhinoconjunctivitis; and (viii) vascular malformations of the brain.

STAT6 is intimately linked to the biology of allergic inflammation. The central and most 406 studied role of STAT6 is in mediating the biological effects of IL-4, a cytokine necessary 407 for T_H2 differentiation, B cell survival, proliferation and class switching to IgE^{9,42}, and 408 driving M2 macrophage polarization⁵⁹. In T cells, STAT6 activation induces the 409 410 expression of GATA3, the master regulator of T_{H2} differentiation, which in turn enhances expression of IL-4, IL-5 and IL-13, cytokines necessary for promoting allergic 411 responses by activating mast cells and eosinophils⁶⁰. Presence of greater T_H2 cell 412 populations, or T_H2 cells producing copious amounts of IL-4/IL-5/IL-13, could be a driver 413 of the observed allergic phenotype presented in our patients. Elevated IgE in 414 partnership with mast cells is important for both acute and chronic manifestations of 415 allergic disorders and can be an additional driver of the allergic diathesis⁶¹. STAT6 416 hyperactivation in airway epithelial cells and resident dendritic cells can further create 417 an environment favouring asthma and chronic lung disease, as this would induce 418 production of chemokines that promote T_H2 cells and eosinophil recruitment^{62,63}. 419 Population genetics provide further support for the central role that STAT6 plays in the 420 development of human allergic disease. Multiple independent genome wide association 421

Human germline STAT6 gain-of-function variants

Sharma et al.

studies (GWAS) have found that polymorphisms in *STAT6* associate with many allergic
conditions (**Table 2**). Our study further expands this appreciation of the role of STAT6 in
human disease by establishing that heterozygous GOF variants cause a monogenic
form of severe allergic disease.

The fatal cerebral aneurysm in P1 (p.E382Q) was not clinically anticipated, but it is 426 possible that the STAT6 GOF variant also increased the risk of developing cerebral 427 aneurysms. Intracranial aneurysms have been reported in patients with both STAT3 428 LOF and STAT1 GOF⁶⁴⁻⁶⁶. Increased activation of other STAT family members, 429 including STAT2, STAT3 and STAT5 have also been observed in human abdominal 430 431 aortic aneurysms (STAT6 was not evaluated), although it is not clear whether enhanced STAT phosphorylation contributes to aneurysms or is the result of inflammation caused 432 433 by aneurysms⁶⁷. As more individuals with STAT6 GOF variants are identified, the possibility of cerebral vascular anomalies warrants investigation. 434

A GOF STAT6 model (designated STAT6VT) has previously been described in vitro⁶⁸ 435 and has been used to study chronic atopic dermatitis in mouse models^{69,70}. STAT6VT 436 has the substitution of two amino acid residues, at positions 547 and 548, in the SH2 437 domain resulting in a STAT6 mutant that is constitutively active in an IL-4 independent 438 manner and is unresponsive to IL-4 stimulation⁶⁸. STAT6VT differs from the variants we 439 describe as the latter are in the DNA binding domain (Fig 1) and do respond to IL-4 440 stimulation (Fig 2-4). Nevertheless, the humans we identified with STAT6 GOF variants 441 and STAT6VT mice share a number of key features of the allergic diathesis, including 442 elevated serum IgE and chronic atopic dermatitis. 443

There is now a growing list of human single gene defects that cause the classic hyperIgE phenotypic triad of eczema, recurrent skin and lung infections, and elevated serum
IgE^{26,71}. Autosomal dominant hyper-IgE syndrome caused by dominant negative
variants in *STAT3* (aka. Job's syndrome or STAT3 LOF) is the best characterized of
these conditions, but this list of disorders does include both autosomal dominant
(*STAT3*, *CARD11*, *ERBIN*) and autosomal recessive (*DOCK8*, *PGM3*, *IL6ST*)
conditions^{72,73}. Notably, the patients we identified with STAT6 GOF variants did have

Human germline STAT6 gain-of-function variants

Sharma et al.

some of the extra-immunological features typical of STAT3 LOF (i.e. hyperextensible
joints, fractures, vascular anomalies⁷³).

Based on the findings reported in this study, we suggest that heterozygous GOF 453 454 variants in STAT6 be added to the list of autosomal dominant causes of the hyper-IgE phenotype. While each of the conditions known to cause a hyper-IgE phenotype has 455 some specific clinical features (e.g. viral skin infections are a defining feature of DOCK8 456 deficiency^{74,75}), there is considerable clinical overlap and clinically-approved testing of 457 these pathways is rarely available. Therefore, we recommend genetic testing as the 458 most efficient initial diagnostic approach to patients who experience severe allergic 459 disease beginning very early in life. Finally, in common with other primary atopic 460 disorders³¹, we demonstrate that JAK inhibition may be an effective treatment for 461 462 patients with GOF STAT6 variants.

While this study has many strengths, notably the extreme allergic phenotype of the two 463 patients combined with in-depth functional assessment of their *de novo* STAT6 variants, 464 a limitation is our lack of validation in primary patient cells due to the death of P1 and 465 challenges with phlebotomy in P2 due to the severity of her atopic dermatitis. Despite 466 this limitation, our study does identify GOF variants in STAT6 as a novel monogenic 467 allergic disorder. We anticipate that this discovery will facilitate the recognition of more 468 affected individuals and, with time, a full definition of the human phenotype caused by 469 germline human STAT6 GOF variants will emerge. 470

- 471
- 472
- 473
- 474
- 475
- 476
- 477

Human germline STAT6 gain-of-function variants

Sharma et al.

478	Acknowledgements: This work was supported by grants from the Canadian Institutes
479	of Health Research (PJT 178054) (S.E.T.), Genome British Columbia (SIP007) (S.E.T.),
480	and BC Children's Hospital Foundation. S.E.T. holds a Tier 1 Canada Research Chair in
481	Pediatric Precision Health and the Aubrey J. Tingle Professor of Pediatric Immunology.
482	M.S. is supported by a CIHR Frederick Banting and Charles Best Canada Graduate
483	Scholarships Doctoral Award (CGS-D) and University of British Columbia Four Year
484	Doctoral Fellowship (4YF). H.Y.L. is supported by a CGS-D, 4YF, Killam Doctoral
485	Scholarship, Friedman Award for Scholars in Health, and a BC Children's Hospital
486	Research Institute Graduate Studentship. M.V.S. is funded by the Vanier Canada
487	Graduate Scholarship and the University of British Columbia 4-Year Doctoral Fellowship
488	(4YF). We would also like to acknowledge the Biomedical Research Centre Sequencing
489	Core (BRC-Seq) for their assistance with RNA-Sequencing and processing.

490

- 491 **Contribution:** Me.S., G.B.R, H.M.B, Mi.S, M.L.M, H.A, K.L.D., and S.E.T enrolled
- 492 patients and analyzed clinical data; J.J.L, A.M, W.W.W., C.D.M.v.K conducted genetic
- 493 screening and identified variants of significance. M.S., O.F, R.v.d.L, and P.A.R
- 494 performed, structural modeling, bioinformatic and statistical analysis; M.S., H.Y.L.,
- 495 M.V.S, K.L.D, S.L., and J.D. performed the laboratory experiments; M.S., H.Y.L., M.V.S,
- and S.E.T. wrote and edited the manuscript. All authors reviewed the final manuscript.

497

498 **Conflict of Interest Disclosures:** Authors report no conflicts of interest in relation to 499 this manuscript.

Human germline STAT6 gain-of-function variants

Sharma et al.

500 **REFERENCES**

1. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012;36:542-50.

Luo Y, Alexander M, Gadina M, O'Shea JJ, Meylan F, Schwartz DM. JAK-STAT
 signaling in human disease: From genetic syndromes to clinical inhibition. J Allergy Clin
 Immunol 2021;148:911-25.

Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine
 signaling and myeloproliferative disorders: approaches for targeted therapies. Genes
 Cancer 2010;1:979-93.

4. Villarino AV, Kanno Y, Ferdinand JR, O'Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 2015;194:21-7.

5.1 Ihle JN. Cytokine receptor signalling. Nature 1995;377:591-4.

- 6. Mogensen TH. IRF and STAT Transcription Factors From Basic Biology to
- Roles in Infection, Protective Immunity, and Primary Immunodeficiencies. FrontImmunol 2018;9:3047.
- 515 7. Briscoe J, Guschin D, Rogers NC, et al. JAKs, STATs and signal transduction in 516 response to the interferons and other cytokines. Philos Trans R Soc Lond B Biol Sci 517 1996;351:167-71.
- 518 8. Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunologic 519 research 2011;50:87-96.
- 520 9. Takeda K, Tanaka T, Shi W, et al. Essential role of Stat6 in IL-4 signalling. 521 Nature 1996;380:627-30.
- 10. Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 2017;18:374-84.
- 11. Villarino AV, Gadina M, O'Shea JJ, Kanno Y. SnapShot: Jak-STAT Signaling II. Cell 2020;181:1696-.e1.
- Mjosberg J, Bernink J, Golebski K, et al. The transcription factor GATA3 is
 essential for the function of human type 2 innate lymphoid cells. Immunity 2012;37:64959.
- Junttila IS. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and
 IL-13 Receptor Complexes. Front Immunol 2018;9:888.
- 14. Spolski R, Gromer D, Leonard WJ. The gamma c family of cytokines: fine-tuning
 signals from IL-2 and IL-21 in the regulation of the immune response. F1000Res
 2017;6:1872.
- 15. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996;4:313-9.
- 536 16. Saatian B, Rezaee F, Desando S, et al. Interleukin-4 and interleukin-13 cause 537 barrier dysfunction in human airway epithelial cells. Tissue Barriers 2013;1:e24333.
- 537 barner dystunction in numan arway epitnelial cells. Tissue Barners 2013;1:e24333 538 17. Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and
- 539 inflammation. Gut 2012;61:1765-73.
- 18. Oetjen LK, Mack MR, Feng J, et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. Cell 2017;171:217-28 e13.
- 542 19. Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in Children with
- 543 Uncontrolled Moderate-to-Severe Asthma. N Engl J Med 2021;385:2230-40.
- 544 20. Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with
- 545 moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130-9.

Human germline STAT6 gain-of-function variants

Sharma et al.

21. Tomkinson A, Kanehiro A, Rabinovitch N, Joetham A, Cieslewicz G, Gelfand 546 EW. The failure of STAT6-deficient mice to develop airway eosinophilia and airway 547 hyperresponsiveness is overcome by interleukin-5. Am J Respir Crit Care Med 548 1999:160:1283-91. 549 Akimoto T, Numata F, Tamura M, et al. Abrogation of bronchial eosinophilic 550 22. inflammation and airway hyperreactivity in signal transducers and activators of 551 transcription (STAT)6-deficient mice. J Exp Med 1998;187:1537-42. 552 Kuperman D, Schofield B, Wills-Karp M, Grusby MJ. Signal transducer and 553 23. activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-554 induced airway hyperresponsiveness and mucus production. J Exp Med 1998;187:939-555 556 48. 557 24. Lyons JJ, Milner JD. Primary atopic disorders. J Exp Med 2018;215:1009-22. Milner JD. Primary Atopic Disorders. Annu Rev Immunol 2020;38:785-808. 25. 558 26. Vaseghi-Shanjani M, Smith KL, Sara RJ, et al. Inborn errors of immunity 559 manifesting as atopic disorders. J Allergy Clin Immunol 2021;148:1130-9. 560 Asano T, Khourieh J, Zhang P, et al. Human STAT3 variants underlie autosomal 27. 561 dominant hyper-IgE syndrome by negative dominance. J Exp Med 2021:218. 562 Fabre A, Marchal S, Barlogis V, et al. Clinical Aspects of STAT3 Gain-of-28. 563 Function Germline Mutations: A Systematic Review. J Allergy Clin Immunol Pract 564 565 2019;7:1958-69 e9. Ma CA, Xi L, Cauff B, et al. Somatic STAT5b gain-of-function mutations in early 29. 566 onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. Blood 2017;129:650-3. 567 Kanai T, Jenks J, Nadeau KC. The STAT5b Pathway Defect and Autoimmunity. 568 30. Front Immunol 2012;3:234. 569 Del Bel KL, Ragotte RJ, Saferali A, et al. JAK1 gain-of-function causes an 570 31. autosomal dominant immune dysregulatory and hypereosinophilic syndrome. J Allergy 571 Clin Immunol 2017;139:2016-20 e5. 572 Gruber CN, Calis JJA, Buta S, et al. Complex Autoinflammatory Syndrome 32. 573 Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical 574 Function. Immunity 2020;53:672-84 e11. 575 Uzel G, Sampaio EP, Lawrence MG, et al. Dominant gain-of-function STAT1 576 33. mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-577 578 X-linked-like syndrome. J Allergy Clin Immunol 2013;131:1611-23. 579 34. Sharma M, Fu MP, Lu HY, et al. Human germline biallelic complete NFAT1 deficiency causes the triad of progressive joint contractures, osteochondromas, and 580 581 susceptibility to B cell malignancy. medRxiv 2022:2022.01.30.22269378. 582 35. Fung SY, Lu HY, Sharma M, et al. MALT1-Dependent Cleavage of HOIL1 Modulates Canonical NF-kappaB Signaling and Inflammatory Responsiveness. Front 583 584 Immunol 2021;12:749794. Kutner RH. Zhang XY. Reiser J. Production. concentration and titration of 36. 585 pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009;4:495-505. 586 587 37. Lu HY, Sharma M, Sharma AA, et al. Mechanistic understanding of the combined 588 immunodeficiency in complete human CARD11 deficiency. J Allergy Clin Immunol 2021. Li J, Rodriguez JP, Niu F, et al. Structural basis for DNA recognition by STAT6. 589 38. 590 Proc Natl Acad Sci U S A 2016;113:13015-20.

Human germline STAT6 gain-of-function variants

Sharma et al.

591	39. Chen Y, Lun AT, Smyth GK. From reads to genes to pathways: differential								
592	expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-								
593	likelihood pipeline. F1000Res 2016;5:1438.								
594	40. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression								
595	analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.								
596	41. Kulpa DA, Talla A, Brehm JH, et al. Differentiation into an Effector Memory								
597	Phenotype Potentiates HIV-1 Latency Reversal in CD4(+) T Cells. J Virol 2019;93.								
598	42. Elo LL, Jarvenpaa H, Tuomela S, et al. Genome-wide profiling of interleukin-4								
599	and STAT6 transcription factor regulation of human Th2 cell programming. Immunity								
600	2010;32:852-62.								
601	43. Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling								
602	of protein structures and complexes. Nucleic Acids Res 2018;46:W296-W303.								
603	44. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimeraa visualization								
604	system for exploratory research and analysis. J Comput Chem 2004;25:1605-12.								
605	45. Yildiz M, Li H, Bernard D, et al. Activating STAT6 mutations in follicular								
606	lymphoma. Blood 2015;125:668-79.								
607	46. Zamo A, Pischimarov J, Horn H, Ott G, Rosenwald A, Leich E. The exomic								
608	landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion. Br J								
609	Haematol 2018;180:391-4.								
610	47. Rentzsch P, Schubach M, Shendure J, Kircher M. CADD-Splice-improving								
611	genome-wide variant effect prediction using deep learning-derived splice scores.								
612	Genome Med 2021;13:31.								
613	48. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server:								
614	predicting effects of amino acid substitutions on proteins. Nucleic Acids Res								
615	2012;40:W452-7.								
616	49. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting								
617	damaging missense mutations. Nat Methods 2010;7:248-9.								
618	50. Mikita T, Campbell D, Wu P, Williamson K, Schindler U. Requirements for								
619	interleukin-4-induced gene expression and functional characterization of Stat6. Mol Cell								
620	Biol 1996;16:5811-20.								
621	51. Kim Y, Kwon EK, Jeon JH, et al. Activation of the STAT6 transcription factor in								
622	Jurkat 1-cells by the herpesvirus saimiri Tip protein. J Gen Virol 2012;93:330-40.								
623	52. Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunol Res								
624									
625	53. Bettigole SE, Lis R, Adoro S, et al. The transcription factor XBP1 is selectively								
626	required for eosinophil differentiation. Nat immunol 2015;16:829-37.								
627	54. Frischmeyer-Guerrerio PA, Guerrerio AL, Oswald G, et al. I GEbeta receptor								
628	mutations impose a strong predisposition for numan allergic disease. Sci Transi Med								
629	2013;5:195/a94.								
630	55. Tate JG, Bamford S, JUDD HC, et al. COSMIC: the Catalogue Of Somatic								
631	Wutations in Cancer. Nucleic Acids Res 2019;47:D941-D7.								
632	binding demain in primary mediacting P call human area. Placed 2000;444:4020, 40								
633	Dinuing uomain in primary mediasilinal B-cell lymphoma. Blood 2009;114:1236-42.								
634 635	bissonnelle R, Papp RA, Poulin T, et al. Topical totacilinit for atopic dermatilis: a								
035	$p_{10} = 10 + 100 + 112 + 0 + 100 $								

Human germline STAT6 gain-of-function variants

Sharma et al.

58. Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib 636 cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol 637 2020;145:572-82. 638 59. Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the 639 multidimensional concept of macrophage ontogeny, activation and function. Nat 640 641 Immunol 2016;17:34-40. Sloka S, Silva C, Wang J, Yong VW. Predominance of Th2 polarization by 642 60. vitamin D through a STAT6-dependent mechanism. J Neuroinflammation 2011;8:56. 643 Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012;18:693-61. 644 704. 645 Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin 646 62. expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir 647 Cell Mol Biol 2001:24:755-61. 648 Medoff BD, Seung E, Hong S, et al. CD11b+ myeloid cells are the key mediators 649 63. of Th2 cell homing into the airway in allergic inflammation. J Immunol 2009;182:623-35. 650 Chandesris MO, Azarine A, Ong KT, et al. Frequent and widespread vascular 64. 651 652 abnormalities in human signal transducer and activator of transcription 3 deficiency. Circ 653 Cardiovasc Genet 2012;5:25-34. Dadak M, Jacobs R, Skuljec J, et al. Gain-of-function STAT1 mutations are 654 65. 655 associated with intracranial aneurysms. Clin Immunol 2017;178:79-85. 66. Toubiana J, Okada S, Hiller J, et al. Heterozygous STAT1 gain-of-function 656 mutations underlie an unexpectedly broad clinical phenotype. Blood 2016;127:3154-64. 657 Liao M, Xu J, Clair AJ, Ehrman B, Graham LM, Eagleton MJ. Local and systemic 658 67. alterations in signal transducers and activators of transcription (STAT) associated with 659 human abdominal aortic aneurysms. J Surg Res 2012;176:321-8. 660 68. Daniel C, Salvekar A, Schindler U. A gain-of-function mutation in STAT6. J Biol 661 662 Chem 2000;275:14255-9. DaSilva-Arnold SC, Thyagarajan A, Seymour LJ, et al. Phenotyping acute and 69. 663 chronic atopic dermatitis-like lesions in Stat6VT mice identifies a role for IL-33 in 664 disease pathogenesis. Arch Dermatol Res 2018;310:197-207. 665 Bruns HA, Schindler U, Kaplan MH. Expression of a constitutively active Stat6 in 666 70. vivo alters lymphocyte homeostasis with distinct effects in T and B cells. J Immunol 667 668 2003;170:3478-87. Freeman AF, Milner JD. The Child with Elevated IgE and Infection Susceptibility. 71. 669 Curr Allergy Asthma Rep 2020;20:65. 670 Minegishi Y. Hyper-IgE syndrome, 2021 update. Allergol Int 2021;70:407-14. 671 72. Bergerson JRE, Freeman AF. An Update on Syndromes with a Hyper-IgE 672 73. Phenotype. Immunol Allergy Clin North Am 2019;39:49-61. 673 674 74. Biggs CM, Keles S, Chatila TA. DOCK8 deficiency: Insights into pathophysiology, clinical features and management. Clin Immunol 2017;181:75-82. 675 Chu EY, Freeman AF, Jing H, et al. Cutaneous manifestations of DOCK8 676 75. 677 deficiency syndrome. Arch Dermatol 2012;148:79-84. 678 76. Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nature Genetics 2021;53:1415-24. 679

Human germline STAT6 gain-of-function variants

Sharma *et al.*

77. Zhu Z, Guo Y, Shi H, et al. Shared genetic and experimental links between 680 obesity-related traits and asthma subtypes in UK Biobank. Journal of Allergy and 681 Clinical Immunology 2020;145:537-49. 682 78. Pividori M, Schoettler N, Nicolae DL, Ober C, Im HK. Shared and distinct genetic 683 risk factors for childhood-onset and adult-onset asthma: genome-wide and 684 transcriptome-wide studies. The Lancet Respiratory Medicine 2019;7:509-22. 685 Ferreira MAR, Mathur R, Vonk JM, et al. Genetic Architectures of Childhood- and 79. 686 Adult-Onset Asthma Are Partly Distinct. The American Journal of Human Genetics 687 2019;104:665-84. 688 Zhu Z, Lee PH, Chaffin MD, et al. A genome-wide cross-trait analysis from UK 689 80. 690 Biobank highlights the shared genetic architecture of asthma and allergic diseases. Nature Genetics 2018;50:857-64. 691 Johansson Å, Rask-Andersen M, Karlsson T, Ek WE. Genome-wide association 692 81. analysis of 350 000 Caucasians from the UK Biobank identifies novel loci for asthma, 693 hay fever and eczema. Human Molecular Genetics 2019;28:4022-41. 694 Zhu Z, Zhu X, Liu C-L, et al. Shared genetics of asthma and mental health 695 82. 696 disorders: a large-scale genome-wide cross-trait analysis. European Respiratory Journal 2019;54:1901507. 697 Demenais F, Margaritte-Jeannin P, Barnes KC, et al. Multiancestry association 698 83. 699 study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nature Genetics 2018;50:42-53. 700 Pickrell JK, Berisa T, Liu JZ, Ségurel L, Tung JY, Hinds DA. Detection and 84. 701 interpretation of shared genetic influences on 42 human traits. Nature Genetics 702 2016;48:709-17. 703 Shrine N, Portelli MA, John C, et al. Moderate-to-severe asthma in individuals of 704 85. European ancestry: a genome-wide association study. The Lancet Respiratory Medicine 705 706 2019;7:20-34. Valette K, Li Z, Bon-Baret V, et al. Prioritization of candidate causal genes for 707 86. asthma in susceptibility loci derived from UK Biobank. Communications Biology 2021:4. 708 Olafsdottir TA, Theodors F, Bjarnadottir K, et al. Eighty-eight variants highlight 709 87. the role of T cell regulation and airway remodeling in asthma pathogenesis. Nature 710 Communications 2020;11. 711 712 88. Han Y, Jia Q, Jahani PS, et al. Genome-wide analysis highlights contribution of immune system pathways to the genetic architecture of asthma. Nature 713 Communications 2020;11. 714 Astle WJ, Elding H, Jiang T, et al. The Allelic Landscape of Human Blood Cell 715 89. Trait Variation and Links to Common Complex Disease. Cell 2016;167:1415-29.e19. 716 Vuckovic D, Bao EL, Akbari P, et al. The Polygenic and Monogenic Basis of 717 90. 718 Blood Traits and Diseases. Cell 2020;182:1214-31.e11. Kachuri L. Jeon S. Dewan AT. et al. Genetic determinants of blood-cell traits 91. 719 influence susceptibility to childhood acute lymphoblastic leukemia. The American 720 721 Journal of Human Genetics 2021;108:1823-35. 722 92. Chen M-H, Raffield LM, Mousas A, et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. Cell 723 724 2020;182:1198-213.e14.

Human germline STAT6 gain-of-function variants

Sharma et al.

- 93. Kichaev G, Bhatia G, Loh P-R, et al. Leveraging Polygenic Functional 725 Enrichment to Improve GWAS Power. The American Journal of Human Genetics 726 2019;104:65-75. 727 728 94. Ferreira MAR, Vonk JM, Baurecht H, et al. Age-of-onset information helps 729 identify 76 genetic variants associated with allergic disease. PLOS Genetics 730 2020;16:e1008725. Ferreira MA, Vonk JM, Baurecht H, et al. Shared genetic origin of asthma, hay 731 95. fever and eczema elucidates allergic disease biology. Nature Genetics 2017;49:1752-7. 732 Tanaka N, Koido M, Suzuki A, et al. Eight novel susceptibility loci and putative 733 96. causal variants in atopic dermatitis. Journal of Allergy and Clinical Immunology 734 735 2021;148:1293-306. 97. Granada M, Wilk JB, Tuzova M, et al. A genome-wide association study of 736 plasma total IgE concentrations in the Framingham Heart Study. Journal of Allergy and 737 738 Clinical Immunology 2012;129:840-5.e21. Daya M, Cox C, Acevedo N, et al. Multiethnic genome-wide and HLA association 739 98. study of total serum IgE level. Journal of Allergy and Clinical Immunology 740 741 2021;148:1589-95. Waage J, Standl M, Curtin JA, et al. Genome-wide association and HLA fine-742 99. 743 mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. 744 Nature Genetics 2018;50:1072-80. Bønnelykke K, Matheson MC, Pers TH, et al. Meta-analysis of genome-wide 745 100. association studies identifies ten loci influencing allergic sensitization. Nature Genetics 746 2013;45:902-6. 747
 - 101. Sleiman PMA, Wang M-L, Cianferoni A, et al. GWAS identifies four novel
 eosinophilic esophagitis loci. Nature Communications 2014;5:5593.
 - 750

Human germline STAT6 gain-of-function variants

Sharma et al.

752 **TABLES**

753 **Table 1: Major Clinical Features**. Tabulation and comparison of the clinical phenotype

of patient 1 and 2.

	Patient 1	Patient 2		
Ganatia Warkun	Heterozygous STAT6	Heterozygous STAT6		
Genetic Workup	c.1144G>C, p.E382Q	c.1256A>G, p.D419G		
Severe Atopic Disease				
Disease onset in early infancy	\checkmark	\checkmark		
Severe, widespread treatment-	✓	\checkmark		
resistant atopic dermatitis	-	-		
Asthma	~	✓		
Multiple food allergies	✓	✓		
Drug allergies	✓	✓		
Allergic rhinoconjunctivitis	✓	✓		
Infections				
Recurrent respiratory infections	✓	✓		
Recurrent skin infections (e.g.				
Staphylococcus, Candida,	\checkmark	\checkmark		
molluscum)				
Gastrointestinal Disorders				
Early gastro-oesophageal reflux	\checkmark			
disease (GERD)		/		
Eosinophilic esophagitis		×		
Chronic diarrnea, protein iosing				
infiltration duodonal atronby	v			
Skeletal Issues				
Ostopporosis, pathogonic fracturos				
Generalized hypermobility and joint	•			
pain		\checkmark		
Vascular anomalies				
	In late 20s:	Brain MRI in mid-30s (age		
	Thromboembolic ischemia	30-35 years) revealed		
	of 1st and 3rd toes with	multiple anatomical variants		
	severe pain	including anomalous		
		vasculature in the circle of		
		Willis with hypoplastic		
	Mid-30s (age 30-35	vertebrobasilar arteries, a		
	years): Fatal spontaneous	persistent left-sided		
	subarachnoid hemorrhage	congenital trigeminal artery		
	with intraventricular	with tortuosity, and a		
	nemorrhage.	nypoplastic A1 segment of		
		the right anterior carotid		
		artery.		

Human germline STAT6 gain-of-function variants

Sharma et al.

	Adolescence (age 15-20
Other	years): Retinal detachment
	in right eye

755

Human germline STAT6 gain-of-function variants

Sharma *et al.*

757 **Table 2. Number of published genome-wide association (GWAS) studies linking**

758 polymorphisms (SNPs) in *STAT6* to common allergic diseases in the population.

- Significant genome-wide associations (P < $5x10^{-8}$) between STAT6 SNPs and all
- relevant allergic traits were obtained through NHGRI-EBI GWAS Catalog
- 761 (ebi.ac.uk/gwas/).
- 762

Phenotype	Number of published associations	References
Asthma*	13	76-88
Eosinophil count	6	76,89-93
Allergic disease	3	80,94,95
Atopic dermatitis/Eczema	3	81,93,96
Serum IgE level	2	97,98
Allergic sensitization	2	99,100
Allergic rhinitis	1	81
Eosinophilic gastrointestinal disorders	1	101

⁷⁶³ *Includes asthma, childhood-onset asthma, adult-onset asthma, and atopic asthma

764

Human germline STAT6 gain-of-function variants

Sharma et al.

766 FIGURES



Human germline STAT6 gain-of-function variants

Sharma et al.

768 Figure 1: Clinical phenotype of two patients with severe atopic disease. A) Family

- pedigree of the two patients. Filled symbols=affected individual, arrow=proband, unfilled
- symbols=unaffected individual. P1 has the variant p.E382Q, P2 has the variant
- p.D419G. B) Eosinophil frequency in whole blood of P1 and P2. C) IgE concentration in
- whole blood of P1 and P2. **D)** Schematic illustrating the protein domains of STAT6.
- Amino acid location of the variants shown in red. Affected region was aligned to other
- species. Asterisks indicate full conservation. **E)** Structural model of the DNA-STAT6
- homodimer complex. Green=p.E382, Purple=p.D419. Residues marked with an asterisk
- (*) were demonstrated to affect the binding of STAT6 to DNA in a previous study³⁸. **F)**
- 577 STAT6 expression in WT-, p.E382Q-, and p.D419G-STAT6-transfected HEK293 cells.
- **G)** Quantification of relative protein expression in F), n=3. Significance determined
- through a one-way ANOVA and Tukey's post-hoc test.

Human germline STAT6 gain-of-function variants

Sharma et al.



781

782 Figure 2: p.E382Q and p.D419G STAT6 variants lead to increased STAT6 activity

in HEK293 cells. A) Schematic illustrating classical IL-4-mediated STAT6 activation,

dimerization, and phosphorylation. B) Phospho-STAT6 expression in WT-, p.E382Q-,

and p.D419G-transfected HEK293 cells before and after treatment with IL-4 (100ng/mL

for 1h). C) Time course of phospho-STAT6-positive cells after 100ng/mL IL-4

- stimulation in transfected HEK293 cells, n=3. D) Luciferase assay of STAT6 activity on
- a plasmid containing a 4x STAT6 binding site [TTCCCAAGAA] for WT-, p.E382Q-, and
- p.D419G STAT6-transfected HEK293 cells before and after stimulation with IL-4

Human germline STAT6 gain-of-function variants

Sharma et al.

- 790 (100ng/mL for 4h), n=3. One-way ANOVA and Tukey's post-hoc test. *p<0.05, **p<0.01,
- 791 ***p<0.001, ****p<0.0001.

Human germline STAT6 gain-of-function variants

Sharma et al.



Human germline STAT6 gain-of-function variants

Sharma et al.

794 Figure 3: p.E382Q and p.D419G STAT6 variants lead to increased STAT6 activity

- in Jurkat T cells. A) Quantification of phospho-STAT6-positive WT-, p.E382Q-, or
- p.D419G-transduced Jurkat T cells before and after treatment with IL-4 (100ng/mL for
- 1h), n=3. **B)** Principal component analysis (PCA) comparing unstimulated and
- stimulated (100 ng/mL IL-4 for 4 h) WT (green), p.E382Q (blue), p.D419G (purple)
- 799 STAT6 transduced Jurkat T cells. PC1 and PC2 contribution is shown in brackets. C-H)
- Normalized counts comparing stimulated WT (green) vs. p.E382Q (blue) or p.D419G
- (purple), for C) XBP1, D) TGFBR2, E) EPAS1, F) BATF, G) IL4R, H) CISH. I) Heatmap
- representation of normalized counts of a transcription set defined as IL-4 targets in each
- 803 STAT6 Jurkat T cells. *adjusted P-val<0.05. J) GSEA plots for curated STAT6 and IL-4-
- TH2 targets genes, comparing WT vs. either p.E382Q (blue) or p.D419G (purple) at both
- baseline and after stimulation with IL-4. Normalized enrichment score (NES) and
- adjusted p-value are shown. K) Sample level enrichment analyses (SLEA) of
- significantly enriched immune pathways from MSigDB Hallmark in unstimulated and IL-
- 4-stimulated samples, comparing WT vs either p.E382Q or p.D419G. Heatmap is
- normalized across the rows and shown as relative expression.

Human germline STAT6 gain-of-function variants

Sharma et al.

811



812

813 Figure 4: JAK inhibitor treatment decreases gain-of-function STAT6 activity

- caused by p.E382Q and p.D419G STAT6. A) phospho-STAT6 expression in
- transfected HEK293 cells pre-treated with ruxolitinib (10µM 2hr) or tofacitinib (4µM 2hr),
- before and after stimulation with IL-4 (100ng/mL 1h). **B)** Quantification of A), n=3. One-
- way ANOVA and Tukey's post-hoc test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Sharma et al.

Human germline STAT6 gain-of-function variants

819 SUPPLEMENTAL FIGURES

820



- 821
- 822

823 Supplementary Figure 1: Extended data on STAT6 variant-transduced Jurkat T

cells. A) Significantly upregulated (i) and downregulated (ii) genes upon IL-4 treatment in WT (green), p.E382Q (blue) and p.D419G (purple) in Jurkat cells as shown via Venn

- 826 diagram.
- 827
- 828

Human germline STAT6 gain-of-function variants

Sharma et al.

829 SUPPLEMENTAL TABLES

830 **Supplementary Table 1:** Variant annotation and pathogenicity prediction of the variants

reported in the two patients.

000	Variant Annota	ation			
052		P1	P2		
000	Chromosome	12	12		
000	Genomic Position (GRCh37)	57498315	57496661		
834	cDNA Position (NM_001178079.2)	1144	1256		
	Nucleotide Reference	G	А		
	Nucleotide Variant	С	G		
	Protein Variant (NP 001171550.1)	p.Glu382GIn (p.E382Q)	p.Asp419Gly (p.D419G)		
	Zygosity	Heterozygous	Heterozygous		
	Inheritance	de novo	de novo		
	dbSNP153	No entry	No entry		
	gnomAD (v3.1.1) No entry		No entry		
	COSMIC (v95)	Somatic not reported	Somatic reported, 26 entries (COSV55668829)		
	in silico	Pathogenicity Prediction	Models		
	CADD (v1.6)	27.7	29.3		
	SIFT	Deleterious (0.026)	Deleterious (0.001)		
	PolyPhen-2	Probably Damaging (1)	Probably Damaging (1)		
	LRT	Deleterious (0)	Deleterious (0)		
	MutationTaster	Disease Causing (1)	Disease Causing (1)		
	PROVEAN	Damaging (-2.71)	Damaging (-4.83)		
	MetaSVM	Tolerable (-0.538)	Damaging (0.610)		
	M-CAP	Possibly pathogenic (0.106)	Possibly pathogenic (0.294)		
	FATHMM MKL Coding	Deleterious (0.986)	Deleterious (0.701)		

Human germline STAT6 gain-of-function variants

Sharma et al.

835 Supplementary Table 2: IL-4/STAT6 target genes in Jurkat. IL-4/STAT6 target genes

- are shown that were either upregulated (green) or downregulated (red) in WT-STAT6
- transduced Jurkat after stimulation with IL-4 (100ng/mL) for 4 hours.

IL4-STAT6 targets in Jurkat							
SOCS1	STK17B	IRF2BP2	IDI1				
MAL	SLC39A8	UBE2B	CHST2				
FAM171A1	MZT1	TEX30	RPF2				
CD244	MBNL1	ABCD3	LYPLA1				
BCL6	ETS2	SCOC	CCNC				
IL4R	PMAIP1	NDUFA5	CENPH				
CISH	ENDOD1	SNX10	CBX3				
RAB11FIP1	TMED7	LZTFL1	HINT3				
TREML2	ST8SIA4	COX20	XIAP				
SNTB1	PRKCQ-AS1	GRK6	CD164				
PECAM1	TSNAX	LINC00493	STK17A				
GCSAM	NDUFB5	DCK	DSTN				
RASGRP1	XBP1	STAMBPL1	ARPC5				
GATSL3	RFK	SGCB	RAP1GAP				
FAM120AOS	TESPA1	DENR	CLSTN3				

838

839

Human germline STAT6 gain-of-function variants

Sharma et al.

841 **Supplementary Table 3:** Statistics for enrichment analysis done on Jurkat T cells,

comparing WT-STAT6 with either p.E382Q or p.D419G at baseline or after stimulation.

	Unsti	m - 1144	vs WT	Unstim - 1256 vs WT			IL4 stim - 1144 vs WT			IL4 stim - 1256 vs stim		
Pathways	NES	pval	qval	NES	pval	qval	NES	pval	qval	NES	pval	qval
MYC_V1	0.55	1	0.997	2.77	<0.0001	<0.0001	-0.93	0.638	0.608	2.81	<0.0001	<0.0001
E2F	1.04	0.364	0.61	2	<0.0001	<0.0001	1.18	0.113	0.429	2.98	<0.0001	0.001
MYC_V2	-1.23	0.157	0.253	2.01	<0.0001	<0.0001	-1.53	0.017	0.044	2.02	<0.0001	<0.0001
OXPHOS	1.4	0.007	0.156	1.82	<0.0001	0.003	-0.71	0.98	0.942	1.43	0.008	0.069
DNA repair	1.01	0.409	0.622	1.63	<0.0001	0.016	0.66	1	0.976	1.39	<0.0001	0.069
G2M	0.68	0.998	1	1.49	<0.0001	0.043	0.86	0.825	0.93	1.77	<0.0001	0.009